MEIJI SEIKA PHARMA CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 1916-10-09
- Employees
- 5K
- Market Cap
- -
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
Phase 3
Recruiting
- Conditions
- Hospital-acquired Bacterial PneumoniaComplicated Intra-abdominal InfectionVentilator-associated Bacterial PneumoniaComplicated Urinary Tract InfectionAcute Pyelonephritis
- Interventions
- Drug: BATDrug: co-administration of cefepime and nacubactamDrug: co-administration of aztreonam and nacubactam
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05905055
- Locations
- 🇯🇵
Meiji Research Site, Nankoku, Kochi, Japan
Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
Phase 3
Completed
- Conditions
- Complicated Urinary Tract InfectionAcute Pyelonephritis
- Interventions
- Drug: co-administration of aztreonam and nacubactamDrug: imipenem/cilastatinDrug: co-administration of cefepime and nacubactam
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 614
- Registration Number
- NCT05887908
- Locations
- 🇪🇪
Meiji Research Site, Meegomäe, Voru, Estonia
A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT02927353
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
Phase 1
Completed
- Conditions
- Pneumonia, Bacterial
- Interventions
- Drug: ME1100 inhalation solution
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02459158
A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595
Phase 1
Completed
- Conditions
- Healthy VolunteersBacterial Infections
- Interventions
- Drug: OP0595Drug: Placebo
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02134834
Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT02100917
Efficacy and Safety Study of ME1111 in Patients With Onychomycosis
Phase 2
Completed
- Conditions
- Onychomycosis
- Interventions
- Drug: ME1111 Solution, High strengthDrug: Matching Vehicle SolutionDrug: ME1111 Solution, Low strength
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 304
- Registration Number
- NCT02022215
Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ME1100 inhalation solution
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT01961830
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ME1100 inhalation solutionDrug: ME1100 placebo inhalation solution
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT01907776
- Locations
- 🇺🇸
WCCT Global, LLC, Cypress, California, United States
Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients
Phase 1
Completed
- Conditions
- Onychomycosis
- Interventions
- Drug: ME1111 solutionDrug: Vehicle Solution
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT01841996
© Copyright 2025. All Rights Reserved by MedPath